These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 28578701)

  • 1. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.
    Ghassem-Zadeh S; Gaida MM; Szanyi S; Acha-Orbea H; Frossard JL; Hinz U; Hackert T; Strobel O; Felix K
    J Transl Med; 2017 Jun; 15(1):126. PubMed ID: 28578701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Diagnosis of Autoimmune Pancreatitis From Pancreatic Cancer by Analysis of Serum Gelatinase Levels.
    Felix K; Dobiasch S; Gaida MM; Schneider K; Werner J; Martens E; Vandooren J; Opdenakker G
    Pancreas; 2016 Aug; 45(7):1048-55. PubMed ID: 26692441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.
    Akamatsu M; Makino N; Ikeda Y; Matsuda A; Ito M; Kakizaki Y; Saito Y; Ishizawa T; Kobayashi T; Furukawa T; Ueno Y
    PLoS One; 2016; 11(7):e0158669. PubMed ID: 27380024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of serum IgG, IgG4 and carbonic anhydrase II antibodies in distinguishing autoimmune pancreatitis from pancreatic cancer and chronic pancreatitis.
    Talar-Wojnarowska R; Gąsiorowska A; Olakowski M; Dranka-Bojarowska D; Lampe P; Śmigielski J; Kujawiak M; Grzegorczyk J; Małecka-Panas E
    Adv Med Sci; 2014 Sep; 59(2):288-92. PubMed ID: 25194335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
    Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
    Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of magnetic resonance elastography in differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma: A preliminary study.
    Shi Y; Cang L; Zhang X; Cai X; Wang X; Ji R; Wang M; Hong Y
    Eur J Radiol; 2018 Nov; 108():13-20. PubMed ID: 30396645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Novel Serum Autoantibodies for Differential Diagnosis of Autoimmune Pancreatitis and Pancreatic Ductal Adenocarcinoma.
    Felix K; Hauck O; Schnölzer M; Kempf T; Warnken U; Schneider K; Bergmann F; Fritz S; Werner J
    Pancreas; 2016 Oct; 45(9):1309-19. PubMed ID: 27623556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic ductal adenocarcinoma with autoimmune pancreatitis-like histologic and immunohistochemical features.
    Zhang X; Liu X; Joseph L; Zhao L; Hart J; Xiao SY
    Hum Pathol; 2014 Mar; 45(3):621-7. PubMed ID: 24457081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.
    Rychlíková J; Vecka M; Jáchymová M; Macášek J; Hrabák P; Zeman M; Vávrová L; Řoupal J; Krechler T; Ák A
    Cancer Biomark; 2016 Jun; 17(1):55-65. PubMed ID: 27314293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating Mass-Forming Autoimmune Pancreatitis From Pancreatic Ductal Adenocarcinoma on the Basis of Contrast-Enhanced MRI and DWI Findings.
    Choi SY; Kim SH; Kang TW; Song KD; Park HJ; Choi YH
    AJR Am J Roentgenol; 2016 Feb; 206(2):291-300. PubMed ID: 26797355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma.
    Pak LM; Schattner MA; Balachandran V; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Allen PJ
    HPB (Oxford); 2018 Feb; 20(2):182-187. PubMed ID: 29033025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Autoantibody Signatures in Sera of Patients with Pancreatic Cancer, Chronic Pancreatitis and Autoimmune Pancreatitis: A Protein Microarray Profiling Approach.
    Ghassem-Zadeh S; Hufnagel K; Bauer A; Frossard JL; Yoshida M; Kutsumi H; Acha-Orbea H; Neulinger-Muñoz M; Vey J; Eckert C; Strobel O; Hoheisel JD; Felix K
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
    Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
    Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB
    J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
    Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
    Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and treatment of autoimmune pancreatitis types 1 and 2.
    Fritz S; Bergmann F; Grenacher L; Sgroi M; Hinz U; Hackert T; Büchler MW; Werner J
    Br J Surg; 2014 Sep; 101(10):1257-65. PubMed ID: 25047016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic duct "Icicle sign" on MRI for distinguishing autoimmune pancreatitis from pancreatic ductal adenocarcinoma in the proximal pancreas.
    Kim HJ; Kim YK; Jeong WK; Lee WJ; Choi D
    Eur Radiol; 2015 Jun; 25(6):1551-60. PubMed ID: 25501271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.